Janssen Research & Development, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$2.0B
Doctors Paid
2,349
Transactions
190,474
2024 Total
$345.0M
Payment Breakdown by Category
Research$1.9B (98.3%)
Consulting$25.0M (1.3%)
Royalty/License$2.2M (0.1%)
Travel$1.5M (0.1%)
Food & Beverage$380,566 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9B | 174,442 | 98.3% |
| Consulting Fee | $25.0M | 5,153 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.0M | 80 | 0.2% |
| Royalty or License | $2.2M | 63 | 0.1% |
| Travel and Lodging | $1.5M | 3,070 | 0.1% |
| Food and Beverage | $380,566 | 7,647 | 0.0% |
| Grant | $70,000 | 3 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $6,800 | 16 | 0.0% |
Payments by Type
Research
$1.9B
174,442 transactions
General
$33.2M
16,032 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | $166.9M | 0 | 3,133 |
| A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | $143.6M | 0 | 3,755 |
| A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | $57.3M | 0 | 5,830 |
| A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | $40.0M | 0 | 193 |
| 70033093AFL3002 | $35.7M | 0 | 3,167 |
| An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | $31.9M | 1 | 3,070 |
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer's Dementia | $24.1M | 1 | 579 |
| A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | $20.6M | 1 | 1,842 |
| A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | $19.4M | 0 | 1,445 |
| A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma | $17.6M | 0 | 430 |
| A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma | $16.9M | 0 | 921 |
| A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. | $16.6M | 0 | 1,264 |
| A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma | $15.3M | 0 | 1,412 |
| A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | $14.2M | 0 | 1,977 |
| Phase II/III randomized, double-blind, placebo-controlled multicenter study of 2 potential disease modifying therapies in individuals at risk for and with dominantly inherited Alzheimers Disease | $13.5M | 0 | 16 |
| A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 | $13.3M | 0 | 414 |
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | $12.9M | 0 | 830 |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | $12.8M | 1 | 3,679 |
| A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | $12.6M | 0 | 88 |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | $12.4M | 0 | 340 |
| A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | $12.2M | 0 | 706 |
| A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | $11.6M | 0 | 2,987 |
| A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma | $11.0M | 0 | 590 |
| 78934804CRD2001 | $10.6M | 0 | 3,933 |
| A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma | $10.5M | 0 | 367 |
| An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | $9.6M | 0 | 815 |
| A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized GPRC5D x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | $9.3M | 0 | 172 |
| Research agreement between Beth Israel Deaconess Medical Center, Inc. and Janssen Pharmaceuticals Inc. | $9.2M | 0 | 6 |
| A multi center prospective long term observational registry of pediatric patients with IBS | $9.0M | 0 | 795 |
| A Phase 3 Study of Androgen Annihilation in High-risk Biochemically Relapsed Prostate Cancer | $9.0M | 0 | 97 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| George Karpouzas, M.d, M.D | Rheumatology | Torrance, CA | $125,462 | $0 |
| Dr. Takman Mack, M.d, M.D | General Practice | Gricignano Di Aversa, CE | $124,000 | $0 |
| Ramon Leon, Md, MD | Family Medicine | Miami, FL | $122,619 | $0 |
| Attaya Suvannasankha, M.d, M.D | Hematology | Indianapolis, IN | $121,170 | $0 |
| Dr. Peter Shalit, M.d, M.D | Internal Medicine | Seattle, WA | $118,794 | $0 |
| Dr. Richard Colletti, M.d, M.D | Pediatric Gastroenterology | Burlington, VT | $113,880 | $0 |
| Dr. Belkis Delgado, M.d, M.D | Internal Medicine | Miami Springs, FL | $113,454 | $0 |
| Olga Antipova | General Practice | Santa Rosa, CA | $107,416 | $0 |
| Dr. Joseph Gathe, M.d, M.D | Infectious Disease | Houston, TX | $107,225 | $0 |
| Peter Jenkin, Md, MD | Dermatology | Manchester, NH | $106,538 | $0 |
| Sergio Jaramillo, Md, MD | Neurology | Miami, FL | $105,823 | $0 |
| Anthony Mills, Md, MD | Internal Medicine | West Hollywood, CA | $105,636 | $0 |
| Dr. Rohit Aggarwal, M.d, M.D | Rheumatology | Pittsburgh, PA | $103,726 | $0 |
| Paul Pollack, M.d, M.D | Neonatal-Perinatal Medicine | Bexley, OH | $99,462 | $0 |
| Dr. Vamsi Mootha, M.d, M.D | Internal Medicine | Boston, MA | $98,503 | $0 |
| Chandan Guha, Md, MD | Radiation Oncology | Bronx, NY | $98,189 | $0 |
| Dr. Gary Peters, M.d, M.D | Internal Medicine | West Chester, PA | $95,966 | $0 |
| Sheldon Preskorn, Phd, PHD | Psychiatry | Wichita, KS | $95,567 | $0 |
| Harpaul Gill, Md, MD | Neurology | Cypress, TX | $95,476 | $0 |
| Dr. Adolfo Cueli, M.d, M.D | Family Medicine | Homestead, FL | $95,237 | $0 |
| Emelina Arocha, M.d, M.D | Psychiatry | Miami, FL | $93,094 | $0 |
| Michael Fabrizio, M.d, M.D | Urology | Washington, DC | $91,490 | $0 |
| Gail Roboz, Md, MD | Internal Medicine | New York, NY | $88,787 | $0 |
| Dr. Arjun Sinha, M.d, M.D | Nephrology | Indianapolis, IN | $88,675 | $0 |
| Dr. Joseph Mikhael, M.d, M.D | Hematology | Scottsdale, AZ | $87,740 | $0 |
Ad
Top Products
- DARZALEX $72.6M
- TREMFYA $45.2M
Associated Products (24)
- TREMFYA $91.7M
- DARZALEX $89.9M
- ERLEADA $54.6M
- STELARA $46.4M
- TECVAYLI $29.3M
- CARVYKTI $24.7M
- REMICADE $21.7M
- Erleada $18.6M
- ZYTIGA $11.8M
- INVEGA TRINZA $10.9M
- PREZISTA $8.6M
- SIMPONI $7.6M
- YONDELIS $5.3M
- RYBREVANT $4.7M
- EDURANT $4.0M
- TOPAMAX $350,517
- Megadyne $321,996
- SIRUKUMAB $190,669
- AKEEGA $171,771
- CNTO 2476 $132,829
- GUSELKUMAB $79,780
- ARN-509 $12,703
- SIRTURO $11,304
- CNTO 888 $10,437
Payment Categories
- Food & Beverage $380,566
- Consulting $25.0M
- Travel & Lodging $1.5M
- Research $1.9B
- Royalties $2.2M
About Janssen Research & Development, LLC
Janssen Research & Development, LLC has made $2.0B in payments to 2,349 healthcare providers, recorded across 190,474 transactions in the CMS Open Payments database. In 2024, the company paid $345.0M. The top product by payment volume is DARZALEX ($72.6M).
Payments were distributed across 137 medical specialties. The top specialty by payment amount is Internal Medicine ($3.9M to 318 doctors).
Payment categories include: Food & Beverage ($380,566), Consulting ($25.0M), Research ($1.9B), Travel & Lodging ($1.5M), Royalties ($2.2M).
Janssen Research & Development, LLC is associated with 24 products in the CMS Open Payments database, including TREMFYA, DARZALEX, and ERLEADA.